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Background
In a single-center study published more than a decade ago involving patients pre-
senting to the emergency department with severe sepsis and septic shock, mortality 
was markedly lower among those who were treated according to a 6-hour protocol 
of early goal-directed therapy (EGDT), in which intravenous fluids, vasopressors, 
inotropes, and blood transfusions were adjusted to reach central hemodynamic 
targets, than among those receiving usual care. We conducted a trial to determine 
whether these findings were generalizable and whether all aspects of the protocol 
were necessary.
Methods
In 31 emergency departments in the United States, we randomly assigned patients 
with septic shock to one of three groups for 6 hours of resuscitation: protocol-based 
EGDT; protocol-based standard therapy that did not require the placement of a 
central venous catheter, administration of inotropes, or blood transfusions; or usu-
al care. The primary end point was 60-day in-hospital mortality. We tested sequen-
tially whether protocol-based care (EGDT and standard-therapy groups combined) 
was superior to usual care and whether protocol-based EGDT was superior to pro-
tocol-based standard therapy. Secondary outcomes included longer-term mortality 
and the need for organ support.
Results
We enrolled 1341 patients, of whom 439 were randomly assigned to protocol-based 
EGDT, 446 to protocol-based standard therapy, and 456 to usual care. Resuscitation 
strategies differed significantly with respect to the monitoring of central venous 
pressure and oxygen and the use of intravenous fluids, vasopressors, inotropes, and 
blood transfusions. By 60 days, there were 92 deaths in the protocol-based EGDT 
group (21.0%), 81 in the protocol-based standard-therapy group (18.2%), and 86 in 
the usual-care group (18.9%) (relative risk with protocol-based therapy vs. usual 
care, 1.04; 95% confidence interval [CI], 0.82 to 1.31; P = 0.83; relative risk with 
protocol-based EGDT vs. protocol-based standard therapy, 1.15; 95% CI, 0.88 to 
1.51; P = 0.31). There were no significant differences in 90-day mortality, 1-year 
mortality, or the need for organ support.
Conclusions
In a multicenter trial conducted in the tertiary care setting, protocol-based resuscita-
tion of patients in whom septic shock was diagnosed in the emergency department 
did not improve outcomes. (Funded by the National Institute of General Medical 
Sciences; ProCESS ClinicalTrials.gov number, NCT00510835.)
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T here are more than 750,000 cases of severe sepsis and septic shock in the United States each year.1 Most patients 
who present with sepsis receive initial care in the 
emergency department, and the short-term mor-
tality is 20% or more.2,3 In 2001, Rivers et al. re-
ported that among patients with severe sepsis or 
septic shock in a single urban emergency depart-
ment, mortality was significantly lower among 
those who were treated according to a 6-hour 
protocol of early goal-directed therapy (EGDT) 
than among those who were given standard ther-
apy (30.5% vs. 46.5%).4 On the basis of the prem-
ise that usual care lacked aggressive, timely as-
sessment and treatment, the protocol for EGDT 
called for central venous catheterization to mon-
itor central venous pressure and central venous 
oxygen saturation (Scvo2), which were used to 
guide the use of intravenous fluids, vasopressors, 
packed red-cell transfusions, and dobutamine in 
order to achieve prespecified physiological tar-
gets. In the decade since the publication of that 
article, there have been many changes in the man-
agement of sepsis, raising the question of whether 
all elements of the protocol are still necessary.5-7
To address this question, we designed a multi-
center trial comparing alternative resuscitation 
strategies in a broad cohort of patients with septic 
shock. Specifically, we tested whether protocol-
based resuscitation was superior to usual care and 
whether a protocol with central hemodynamic 
monitoring to guide the use of fluids, vasopres-
sors, blood transfusions, and dobutamine was 
superior to a simpler protocol that did not in-
clude these elements.
Me thods
Study Oversight
We conducted the multicenter, randomized Pro-
tocolized Care for Early Septic Shock (ProCESS) 
trial at 31 hospitals in the United States. The 
institutional review board at the University of 
Pittsburgh and at each other participating site 
approved the registered study protocol, which is 
available with the full text of this article at 
NEJM.org. The National Institute of General Med-
ical Sciences funded the study and convened an 
independent data and safety monitoring board 
(see the Supplementary Appendix, available at 
NEJM.org). The Scvo2 monitoring equipment for 
the study was loaned to the sites by Edwards 
Lifesciences, but the company had no other role 
in the study. Study coordinators at each site en-
tered data into a secure Web-based data-collec-
tion instrument. The University of Pittsburgh 
Clinical Research, Investigation, and Systems 
Modeling of Acute Illness (CRISMA) Center man-
aged all the data and generated blinded and un-
blinded reports for the data and safety monitor-
ing board. We reported the statistical analysis 
plan before the data were unblinded.8 The clini-
cal coordinating team and investigators at the 
participating sites remained unaware of the 
study-group outcomes until the data were locked 
in December 2013. The writing committee vouch-
es for the accuracy and completeness of the data 
and for the fidelity of the study to the protocol.
Sites and Patients
All the participating sites were academic hospitals 
with more than 40,000 emergency department 
visits yearly. To be eligible, the study sites had to 
use the measurement of serum lactate levels as 
the method for screening for cryptogenic shock 
and had to adhere to the Surviving Sepsis Cam-
paign guidelines9,10 for nonresuscitation aspects 
of care but could have no routine resuscitation 
protocols for septic shock and could not routine-
ly use continuous Scvo2 catheters. We recruited 
patients in the emergency department in whom 
sepsis was suspected according to the treating 
physician, who were at least 18 years of age, who 
met two or more criteria for systemic inflamma-
tory response syndrome11 (see the Methods sec-
tion in the Supplementary Appendix), and who 
had refractory hypotension or a serum lactate 
level of 4 mmol per liter or higher. We defined 
refractory hypotension as a systolic blood pres-
sure that either was less than 90 mm Hg or re-
quired vasopressor therapy to maintain 90 mm Hg 
even after an intravenous fluid challenge. We ini-
tially required the fluid challenge to be 20 ml or 
more per kilogram of body weight, administered 
over the course of 30 minutes, but in April 2010, 
we simplified the requirement to a challenge of 
1000 ml or more administered over the course of 
30 minutes. Patients did not have to be in shock 
on arrival in the emergency department but had 
to be enrolled in the study in the emergency de-
partment within 2 hours after the earliest detec-
tion of shock and within 12 hours after arrival. 
The exclusion criteria are listed in the Methods 
section in the Supplementary Appendix. All pa-
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tients or their legally authorized representatives 
provided written informed consent. Randomiza-
tion was performed with the use of a centralized 
Web-based program in variable block sizes of 3, 6, 
or 9, with stratification according to site and race.
Study Interventions
We randomly assigned patients, in a 1:1:1 ratio, 
to one of three groups: protocol-based EGDT, 
protocol-based standard therapy, or usual care. 
The same trained and dedicated physician-led 
team implemented both the protocol-based EGDT 
and the protocol-based standard-therapy inter-
ventions. The team consisted of at least one avail-
able physician who was trained in the protocol-
guided resuscitation interventions, a study 
coordinator who monitored adherence to proto-
col instructions and provided timed prompts, 
and a bedside nurse. All study physicians were 
trained in emergency medicine or critical care 
medicine and had completed a Web-based certifi-
cation examination. The protocol-based care be-
gan in the emergency department but could be 
continued elsewhere. Details regarding the train-
ing and conduct of the personnel are provided in 
the Methods section in the Supplementary Ap-
pendix. In cases in which a team physician was 
the bedside provider before enrollment, care was 
transferred to a nonstudy physician before en-
rollment.
For patients randomly assigned to protocol-
based EGDT, the resuscitation team followed the 
protocol outlined in Figure S1 in the Supplemen-
tary Appendix, which mimics that used by Rivers 
et al.4 The protocol prompted placement of a 
central venous catheter to monitor pressure and 
Scvo2 and to administer intravenous fluids, vaso-
pressors, dobutamine, or packed red-cell transfu-
sions, as directed. We did not require placement 
of an arterial catheter for blood-pressure monitor-
ing. The protocol in our study, like the protocol 
in the study by Rivers et al., specified the amount 
and timing, but not the type, of resuscitation fluid. 
Similarly, the protocol in our study specified 
thresholds for vasopressor use but not the specific 
choice of vasopressor. The protocol guided only 
resuscitation, with all other aspects of care, in-
cluding the choice of antimicrobial agents, given 
at the discretion of the treating physician.
Protocol-based standard therapy also used a 
team approach with a set of 6-hour resuscitation 
instructions, but the components were less ag-
gressive than those used for protocol-based 
EGDT (Fig. S2 in the Supplementary Appendix). 
ProCESS investigators designed the protocol-
based standard-therapy approach on the basis of 
a review of the literature, two independent sur-
veys of emergency physician and intensivist 
practice worldwide,5,12 and consensus feedback 
from investigators. Protocol-based standard ther-
apy required adequate peripheral venous access 
(with placement of a central venous catheter only 
if peripheral access was insufficient) and ad-
ministration of f luids and vasoactive agents to 
reach goals for systolic blood pressure and 
shock index (the ratio of heart rate to systolic 
blood pressure) and to address f luid status and 
hypoperfusion, which were assessed clinically 
at least once an hour. In contrast to the triggers 
in the EGDT protocol, protocol-based standard 
therapy recommended packed red-cell transfu-
sion only if the hemoglobin level was less than 
7.5 g per deci liter. The protocol for standard 
therapy mandated administration of f luids un-
til the team leader decided that the patient’s 
f luids were replete. The standard-therapy pro-
tocol, like the EGDT protocol, did not specify 
the type of f luid or vasopressor and did not 
specify nonresuscitation aspects of care, which 
were provided by the treating physician. We as-
sessed adherence to the EGDT and standard-
therapy protocols using an algorithm that screened 
for decision prompts and actions at 2, 4, and 
6 hours (Fig. S3 and S4 in the Supplementary 
Appendix).
For patients in the usual-care group, the bed-
side providers directed all care, with the study 
coordinator collecting data but not prompting 
any actions. Lead investigators at a site could not 
serve as the bedside treating physician for pa-
tients in the usual-care group.
Outcome Measures
The primary outcome of the study was the rate of 
in-hospital death from any cause at 60 days. Sec-
ondary mortality outcomes included the rate of 
death from any cause at 90 days and cumulative 
mortality at 90 days and 1 year. Other outcomes 
included the duration of acute cardiovascular 
failure (defined as the duration of the need for 
vasopressors), acute respiratory failure, and acute 
renal failure (defined as the duration of mechan-
ical ventilation or dialysis during the acute hospi-
talization, truncated at 60 days, in patients who 
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had not had a long-term need for ventilation or 
dialysis before enrollment); the duration of the 
stay in the hospital and intensive care unit; and 
hospital discharge disposition (i.e., discharge to 
a long-term or other acute care facility, a nursing 
home, a private home, or other). We collected in-
formation on serious adverse events using stan-
dard federal guidelines.13
Statistical Analysis
We analyzed all data according to the intention-
to-treat principle. For the primary outcome, our 
design tested sequentially whether protocol-based 
resuscitation (EGDT or standard therapy) was su-
perior to usual care and, if it was, whether proto-
col-based EGDT was superior to protocol-based 
standard therapy. We initially calculated that 
with a sample of 1950 patients, the study would 
have at least 80% power to detect a reduction in 
mortality of 6 to 7 percentage points, at an alpha 
level of 0.05 for both hypotheses, assuming mor-
tality of 30 to 46% with usual care; interim 
 analyses were planned after 650 patients and 
1300 patients had been enrolled. The trial did 
not meet the stopping criteria at the first planned 
interim analysis (after the enrollment of 650 pa-
tients). Before the second interim analysis, we 
observed that the overall mortality was approxi-
mately 20%, which was much lower than antici-
pated but consistent with the results of a recent 
study involving similar patients.14 After consulta-
tion with the data and safety monitoring board 
and the National Institute of General Medical 
Sciences, and with the group assignments still 
concealed, we calculated that we would need to 
enroll a total of 1350 patients to preserve the 
same power for the same absolute risk reduction.
After spending 0.0005 alpha for the first 
 interim analysis, and after recalculation of the 
sample size (which removed the requirement for 
a second interim analysis), the alpha level re-
quired for the sequential hypotheses was 0.0494, 
with no adjustment for multiple testing. We tested 
for between-group differences in the primary out-
come using Fisher’s exact test. In the event that 
protocol-based care (EGDT and standard therapy 
combined) was not superior to usual care, all 
other analyses were to be specified as secondary. 
Because of possible site heterogeneity, we also 
conducted a secondary analysis using a general-
ized linear mixed model in which we allowed for 
a random effect of study site, with treatment 
group as a covariate; assessed significance with 
the use of type 3 tests; and used compound sym-
metry for the covariance structure.
For other end points, we used Fisher’s exact 
test for categorical outcomes and an analysis of 
variance for continuous outcomes. For survival 
analyses, we generated Kaplan–Meier estimates, 
assessed between-group differences using the 
log-rank test, and expressed the data as cumula-
tive mortality curves. In prespecified subgroup 
analyses, we used the Breslow–Day test to assess 
interactions between treatment assignment and 
subgroups defined according to age, sex, race, 
source of infection, and enrollment criterion (re-
fractory hypotension or elevated serum lactate 
level). We also conducted post hoc subgroup 
analyses according to thirds of values for the 
Acute Physiology and Chronic Health Evaluation 
(APACHE) II score, for the baseline serum lactate 
level, and for the time from detection of shock 
until randomization, using logistic regression 
to test for an interaction between treatment as-
signment and subgroups. Unless otherwise 
specified, analyses are for tests of differences 
across the three study groups, with P values of 
less than 0.05 considered to indicate statistical 
significance. We used SAS software, version 9.3, 
for all analyses.
R esult s
Patients
From March 2008 through May 2013, we enrolled 
1351 patients (Fig. 1, and Fig. S5 in the Supple-
mentary Appendix). Ten patients who provided 
informed consent later requested complete with-
drawal from the study, leaving a final cohort of 
1341 patients for the analysis: 439 in the protocol-
based EGDT group, 446 in the protocol-based 
standard-therapy group, and 456 in the usual-
care group. The three groups were well matched 
at baseline with respect to demographic and clini-
cal characteristics, as well as the care received be-
fore randomization (Table 1, and Tables S1, S2, 
and S4 in the Supplementary Appendix).
Adherence to the Protocol
Adherence to the protocol was high in both pro-
tocol-based groups. At 6 hours, incomplete ad-
herence was recorded in 48 of 404 patients in the 
EGDT group (11.9%) and 19 of 435 patients in 
the standard-therapy group (4.4%) who could be 
evaluated (Table S3 in the Supplementary Appen-
dix). In most of the patients who had been ran-
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domly assigned to EGDT, a central venous cath-
eter for monitoring of Scvo2 was placed promptly 
(Fig. S6A in the Supplementary Appendix). The 
reasons for failure to place a central venous cath-
eter, which occurred in 30 of the 439 patients in 
that group (6.8%), included technical difficulties 
(10 patients), refusal by the treating clinician (9) 
or patient (5), the need for emergency surgery (1), 
1351 Underwent randomization
12,707 Patients were screened
8864 Were ineligible
6841 Did not meet inclusion criteria
2659 Did not have hypoperfusion
2294 Did not have refractory hypotension
120 Could not be assessed for refractory 
       hypotension 
993 Did not have suspected infection
621 Did not have ≥2 SIRS criteria
154 Had other reason
2023 Met exclusion criteria
660 Had “Do Not Resuscitate” order
264 Had treating physician who deemed
aggressive care unsuitable
194 Required immediate surgery
165 Had active gastrointestinal hemorrhage
162 Had contraindication to central venous
catheter
95 Had acute coronary syndrome
71 Had major cardiac arrhythmia
71 Had seizure
69 Had acute pulmonary edema
46 Were participating in another interventional
study
42 Had drug overdose
38 Had CD4 count <50/mm3
36 Were transferred from another in-hospital
setting
31 Had acute cerebrovascular event
21 Had absolute neutrophil count <500 mm3
18 Had burn or trauma
12 Had contraindication to blood transfusion
8 Had status asthmaticus
20 Had other reason
2492 Were eligible but excluded
1191 Had study logistic issues
631 Had decreased mental capacity and no LAR
569 Declined to participate
101 Had other reason
445 Were assigned to protocol-based
       EGDT
439 Were eligible for analysis
6 Requested removal of all data
458 Were assigned to usual care
456 Were eligible for analysis
2 Requested removal of all data
439 Were included in primary
outcome analysis
456 Were included in primary
outcome analysis
448 Were assigned to protocol-based
standard therapy
446 Were eligible for analysis
2 Requested removal of all data
446 Were included in primary
outcome analysis
Figure 1. Screening, Randomization, and Follow-up.
EGDT denotes early goal-directed therapy, LAR legally authorized representative, and SIRS systemic inflammatory 
response syndrome.
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and death (1); no reason was provided in the case 
of 4 patients). The mean (±SD) Scvo2 after cath-
eterization was 71±13%. Although placement of 
central venous catheters was not required for pa-
tients in the protocol-based standard-therapy
group or the usual-care group, central venous 
catheters were placed in 56.5% of the patients 
(252 patients) and 57.9% (264 patients) in the 
two groups, respectively; however, placement oc-
curred later than in the EGDT group (P<0.001) 
Table 1. Characteristics of the Patients at Baseline.*
Characteristic
Protocol-Based  
EGDT  
(N = 439)
Protocol-Based  
Standard Therapy  
(N = 446)
Usual Care  
(N = 456)
Age — yr† 60±16.4 61±16.1 62±16.0
Male sex — no. (%) 232 (52.8) 252 (56.5) 264 (57.9)
Residence before admission — no. (%)‡
Nursing home 64 (14.6) 72 (16.1) 73 (16.0)
Other 373 (85.0) 373 (83.6) 382 (83.8)
Charlson comorbidity score§ 2.6±2.6 2.5±2.6 2.9±2.6
Source of sepsis — no. (%)
Pneumonia 140 (31.9) 152 (34.1) 151 (33.1)
Urinary tract infection 100 (22.8) 90 (20.2) 94 (20.6)
Intraabdominal infection 69 (15.7) 57 (12.8) 51 (11.2)
Infection of unknown source 57 (13.0) 47 (10.5) 66 (14.5)
Skin or soft-tissue infection 25 (5.7) 33 (7.4) 38 (8.3)
Catheter-related infection 11 (2.5) 16 (3.6) 11 (2.4)
Central nervous system infection 3 (0.7) 3 (0.7) 4 (0.9)
Endocarditis 1 (0.2) 3 (0.7) 3 (0.7)
Other 28 (6.4) 31 (7.0) 26 (5.7)
Determined after review not to have infection 5 (1.1) 14 (3.1) 12 (2.6)
Positive blood culture — no. (%) 139 (31.7) 126 (28.3) 131 (28.7)
APACHE II score¶ 20.8±8.1 20.6±7.4 20.7±7.5
Entry criterion — no. (%)
Refractory hypotension 244 (55.6) 240 (53.8) 243 (53.3)
Hyperlactatemia‖ 259 (59.0) 264 (59.2) 277 (60.7)
Physiological variables
Systolic blood pressure — mm Hg 100.2±28.1 102.1±28.7 99.9±29.5
Serum lactate — mmol/liter** 4.8±3.1 5±3.6 4.9±3.1
Time to randomization — min
From arrival in the emergency department†† 197±116 185±112 181±97
From meeting entry criteria 72±77 66±38 69±45
* Plus–minus values are means ±SD. There were no significant differences in baseline characteristics across groups (P values 
range from 0.10 to 0.96). EGDT denotes early goal-directed therapy.
† Information on age was missing for one patient in the usual-care group.
‡ Information on residence before admission was missing for four patients. The category of nursing home included personal-
care homes, skilled or unskilled assisted-living facilities, and extended-care facilities.
§ The Charlson comorbidity index15 measures the effect of coexisting conditions on mortality, with scores ranging from 
0 to 33 and higher scores indicating a greater burden of illness.
¶ Scores on the Acute Physiology and Chronic Health Evaluation (APACHE) II range from 0 to 71, with higher scores in-
dicating greater severity of illness.
‖ Hyperlactatemia was defined as a serum lactate level of 4 mmol per liter or higher. The serum lactate level was higher 
than 2 mmol per liter in 346 patients in the protocol-based EGDT group (78.8%), 340 in the protocol-based standard-
therapy group (76.2%), and 359 in the usual-care group (78.7%).
** Data on the baseline serum lactate level were available for 95.5% of the patients overall (1281 of 1341 patients).
†† Not all patients were eligible at the time of arrival in the emergency department.
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(Fig. S6B in the Supplementary Appendix) and 
involved serial monitoring of Scvo2 in only a 
small proportion of patients (4.0% [18 patients] 
in the protocol-based standard-therapy group 
and 3.5% [16 patients] in the usual-care groups, 
vs. 93.6% [411 patients] in the EGDT group; 
P<0.001).
Resuscitation
During the first 6 hours, the volume of intra-
venous fluids administered differed significantly 
among the groups (2.8 liters in the protocol-based 
EGDT group, 3.3 liters in the protocol-based 
standard-therapy group, and 2.3 liters in the usual-
care group (P<0.001) (Table S4 and Fig. S6C in the 
Supplementary Appendix). The volume of fluids 
administered decreased during the 6 hours in all 
the groups, but patients in the protocol-based 
standard-therapy group received the greatest vol-
ume initially and overall, patients in the usual-
care group received the least volume of fluid, and 
patients in the protocol-based EGDT group re-
ceived fluid at the most consistent rate (P<0.001 
for differences in total volume and P = 0.007 for 
differences over time). Crystalloids were the pre-
dominant fluid used in all the groups, adminis-
tered in 96% of the patients overall. More patients 
in the two protocol-based groups than in the 
usual-care group received vasopressors (54.9% in 
the protocol-based EGDT group and 52.2% in the 
protocol-based standard-therapy group vs. 44.1% 
in the usual-care group, P = 0.003) (Table S4 and 
Fig. S6D in the Supplementary Appendix). More 
patients in the protocol-based EGDT group than 
in the protocol-based standard-therapy group or 
the usual-care group received dobutamine and 
packed red-cell transfusions (dobutamine use, 
8.0% vs. 1.1% and 0.9%, respectively; P<0.001; 
packed red-cell transfusions, 14.4% vs. 8.3% and 
7.5%, respectively; P = 0.001) (Table S4, and Fig. 
S6D in the Supplementary Appendix). The use of 
antibiotics, glucocorticoids, and activated pro-
tein C was similar across the three groups (with 
P  values ranging from  0.16 to 0.90) (Table S4 in 
the Supplementary Appendix).
Ancillary Care
The use of intravenous fluids, vasopressors, do-
butamine, and blood transfusions between 6 and 
72 hours did not differ significantly among the 
groups (Table S4 in the Supplementary Appen-
dix). Patients in all three groups had mean values 
that were consistent with low-tidal-volume venti-
lation and moderate glycemic control (Table S4 
in the Supplementary Appendix). In general, the 
condition of the patients in all three groups im-
proved over time, with few differences among 
the groups. By 6 hours, the target mean arterial 
pressure of 65 mm Hg or higher had been 
achieved in more patients in each of the protocol-
based groups than in the usual-care group 
(P = 0.02), but the mean heart rate did not differ 
significantly among the groups (P = 0.32) (Table S2 
in the Supplementary Appendix). Patients in the 
protocol-based EGDT group had a higher mean 
international normalized ratio at 6 hours (2.2, 
vs. 1.7 in the protocol-based standard-therapy 
group and 1.6 in the usual-care group; P = 0.01), 
whereas patients in the usual-care group had 
slightly less acidosis at 6 hours and 24 hours (ar-
terial pH, 7.31 in each protocol-based group vs. 
7.34 in the usual-care group at 6 hours, and 7.34 
in each protocol-based group vs. 7.36 in the 
usual-care group at 24 hours, P = 0.02), but these 
differences did not persist.
Outcomes
By day 60, a total of 92 patients in the protocol-
based EGDT group (21.0%), 81 in the protocol-
based standard-therapy group (18.2%), and 86 in 
the usual-care group (18.9%) had died in the hos-
pital (Table 2). The 60-day in-hospital mortality 
for the combined protocol-based groups (19.5% 
[173 of 885 patients]) did not differ significantly 
from that in the usual-care group (relative risk, 
1.04; 95% confidence interval [CI], 0.82 to 1.31; 
P = 0.83), nor did mortality differ significantly 
when the groups were compared separately (with 
P  values ranging from 0.31 to 0.89) (Table 2 and 
Fig. 2A). There were also no significant differ-
ences in 90-day mortality or in the time to death 
up to 90 days and 1 year (P = 0.66 for 90-day mor-
tality and P = 0.70 and P = 0.92 for cumulative 
mortality at 90 days and 1 year, respectively) 
(Table 2 and Fig. 2B). Results were essentially 
unchanged when adjusted for potential site het-
erogeneity (odds of 60-day in-hospital death with 
protocol-based care vs. usual care, 1.08; 95% CI, 
0.85 to 1.38; P = 0.54).
The incidence of acute renal failure, as indi-
cated by a new need for renal-replacement ther-
apy, was higher in the protocol-based standard-
therapy group than in the other two groups 
(6.0% in the protocol-based standard-therapy 
group vs. 3.1% in the protocol-based EGDT 
group and 2.8% in the usual-care group, P = 0.04), 
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although the duration of therapy did not differ 
significantly across the groups (Table 2). The 
rate of admission to the intensive care unit was 
higher in the protocol-based EGDT group than 
in the other two groups, although among pa-
tients who were admitted, there were no signifi-
cant between-group differences in the length of 
stay in the intensive care unit (Table 2). There 
were no significant differences in the incidence 
and duration of cardiovascular failure or respira-
tory failure, nor were there significant differ-
ences in the length of stay in the hospital or the 
discharge disposition (Table 2).
Reports of potentially serious adverse events 
(excluding death) were rare and did not differ 
significantly across groups (Table 2, and Table S5 
in the Supplementary Appendix). There were no 
significant interactions between the assigned 
treatment and any prespecified subgroup with re-
spect to the primary outcome of 60-day in-hospital 
mortality or with respect to the secondary mortal-
ity outcomes (Table S6 in the Supplementary Ap-
Table 2. Outcomes.*
Outcome
Protocol-based 
EGDT
(N = 439)
Protocol-based 
Standard Therapy 
(N = 446)
Usual Care 
(N = 456) P Value†
Death — no./total no. (%)
In-hospital death by 60 days: primary outcome 92/439 (21.0) 81/446 (18.2) 86/456 (18.9) 0.83‡
Death by 90 days 129/405 (31.9) 128/415 (30.8) 139/412 (33.7) 0.66
New organ failure in the first week — no./total no. (%)
Cardiovascular 269/439 (61.3) 284/446 (63.7) 256/456 (56.1) 0.06
Respiratory 165/434 (38.0) 161/441 (36.5) 146/451 (32.4) 0.19
Renal 12/382 (3.1) 24/399 (6.0) 11/397 (2.8) 0.04
Duration of organ support — days§
Cardiovascular 2.6±1.6 2.4±1.5 2.5±1.6 0.52
Respiratory 6.4±8.4 7.7±10.4 6.9±8.2 0.41
Renal 7.1±10.8 8.5±12 8.8±13.7 0.92
Use of hospital resources
Admission to intensive care unit — no. (%) 401 (91.3) 381 (85.4) 393 (86.2) 0.01
Stay in intensive care unit among admitted 
patients — days
5.1±6.3 5.1±7.1 4.7±5.8 0.63
Stay in hospital — days 11.1±10 12.3±12.1 11.3±10.9 0.25
Discharge status at 60 days — no. (%)
Not discharged 3 (0.7) 8 (1.8) 2 (0.4) 0.82
Discharged to a long-term acute care facility 16 (3.6) 22 (4.9) 22 (4.8)
Discharge to another acute care hospital 8 (1.8) 2 (0.4) 5 (1.1)
Discharged to nursing home 71 (16.2) 93 (20.9) 88 (19.3)
Discharged home 236 (53.8) 227 (50.9) 235 (51.5)
Other or unknown 13 (3.0) 13 (2.9) 18 (3.9)
Serious adverse events — no. (%)¶ 23 (5.2) 22 (4.9) 37 (8.1) 0.32
* Plus–minus values are means ±SD.
† Unless stated otherwise, P values are for a three-group comparison, with the use of Fisher’s exact test for categorical 
measures and linear models for continuous and normally distributed measures. Skewed outcomes were analyzed with 
the use of nonparametric alternatives.
‡ The P value for the primary analysis was for a comparison between the two protocol-based groups combined and the 
usual-care group, with the use of Fisher’s exact test. The three-group comparison, with the use of Fisher’s exact test, was 
also nonsignificant (P = 0.55), as was each one of the two-way comparisons (with P values ranging from  0.31 to 0.89).
§ Included in the analysis were patients in whom new organ failure developed in the first week after randomization.
¶ A detailed list of serious adverse events is provided in Table S5 in the Supplementary Appendix.
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pendix). Similarly, in a post hoc analysis, there 
was no evidence of a treatment effect within 
ranges of values for the APACHE II score, serum 
lactate level, or time from meeting the criteria 
for shock to randomization (Table S7 in the Sup-
plementary Appendix).
Discussion
In our study, adherence to the two experimental 
protocols was high, and, as expected, protocol-
based care, as compared with usual care, result-
ed in increased use of central venous catheteriza-
tion, intravenous fluids, vasoactive agents, and 
blood transfusions. The two protocol-based re-
suscitation approaches led to a small but tran-
sient improvement in blood pressure by the end 
of the resuscitation period but a higher require-
ment for intensive care and renal-replacement 
therapy. There were no significant differences in 
mortality, either overall or in a number of pre-
specified and post hoc subgroups.
Our results differ from those of Rivers et al.4; 
however, our study was not a direct replication 
of that study, and there are probably several fac-
tors that contribute to the differences. Although 
the two trials used similar inclusion criteria, the 
enrolled populations differed. The study cohorts 
were similar with respect to many demographic 
and clinical characteristics, including the sever-
ity of illness (Table S8 in the Supplementary 
Appendix), but the cohort in the study by Rivers 
et al. was slightly older, had higher rates of pre-
existing heart and liver disease, and had a higher 
initial serum lactate level. Although we modified 
the minimum fluid bolus required to establish 
the presence of refractory hypotension, the mean 
volume of the bolus that was administered fell 
within the range used in the study by Rivers et 
al. (20 to 30 ml per kilogram). The mean initial 
Scvo2 reported by Rivers et al. was 49%, which 
was lower than that in the ProCESS trial. How-
ever, early central venous catheterization was 
considered to be part of usual care in that trial, 
allowing Scvo2 readings to be made before ad-
ministration of the initial fluid bolus, the re-
sponse to which was required to establish re-
fractory hypotension. In contrast, for patients 
randomly assigned to the protocol-based EGDT 
group in our study, we measured Scvo2 only after 
the initial fluid bolus had been administered, 
making a direct comparison problematic. None-
theless, the cohort in the study by Rivers et al. 
may have had, on average, more severe or persis-
tent shock than the patients in our cohort. How-
ever, we were unable to show a benefit even 
when we restricted the analyses to the sickest 
third of our patients — those with the highest 
serum lactate levels and those with the highest 
APACHE II scores.
Both trials used the same EGDT protocol 
Protocol-based EGDT Protocol-based 
standard therapy
Usual care
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Figure 2. Cumulative Mortality.
Panel A shows cumulative in-hospital mortality, truncated at 60 days, and 
Panel B cumulative mortality up to 1 year after randomization.
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delivered by a trained, dedicated team at each 
site. Rivers et al. reported nearly perfect adher-
ence but did not provide details regarding the 
assessment method. Although adherence to the 
protocol was high in our study, we cannot ex-
clude the possibility that the outcome would 
have been better if adherence had been perfect. 
We believe that the rate of adherence in our 
study parallels the likely performance in any 
widespread effort targeting the care of patients 
with septic shock. Furthermore, changes during 
the past decade in the care of critically ill pa-
tients, including the use of lower hemoglobin 
levels as a threshold for transfusion, the imple-
mentation of lung-protection strategies, and the 
use of tighter control of blood sugar, may have 
helped lower the overall mortality and may have 
reduced the marginal benefit of alternative re-
suscitation strategies.9,10,16,17
In 2010, Jones et al. reported the results of a 
randomized trial involving a patient population 
similar to ours (Table S8 in the Supplementary 
Appendix). That trial showed that an EGDT pro-
tocol that was based on serial measurement of 
serum lactate levels was not inferior to an EGDT 
protocol that used Scvo2 monitoring.14 In-hospital 
mortality and the use of intravenous fluids, blood 
transfusions, and dobutamine were similar to 
those seen in the ProCESS trial. Other studies 
showing the benefit of EGDT in adults presenting 
to the emergency department with septic shock 
have been observational and open to potential 
confounding.18
There are important limitations to our study. 
First, although we took many steps to ensure 
close adherence to the resuscitation protocols, 
we cannot be sure that elements critical to the 
success of the protocol in the study by Rivers et 
al. were not lost during dissemination. Second, 
we enrolled patients who were recognized to be 
in septic shock. Our study does not address the 
extent to which any of these strategies offer ad-
vantages in settings where septic shock is not 
recognized promptly. Third, septic shock occurs 
in a heterogeneous population, and care before 
randomization can be variable. Fourth, we had 
limited power to address whether particular strat-
egies were more effective in specific subgroups. 
Two ongoing multicenter trials of EGDT, the 
Australasian Resuscitation in Sepsis Evaluation 
(ARISE) trial in Australia (ClinicalTrials.gov num-
ber, NCT00975793) and the Protocolised Man-
agement in Sepsis (ProMISe) trial in the United 
Kingdom (Current Controlled Trials number, 
ISRCTN36307479) may offer additional insight.19,20 
Finally, in-hospital mortality among patients 
requiring life support is strongly influenced by 
varying practices regarding the withdrawal of 
care, which could have influenced our findings.
In summary, in our multicenter, randomized 
trial, in which patients were identified early in 
the emergency department as having septic 
shock and received antibiotics and other nonre-
suscitation aspects of care promptly, we found 
no significant advantage, with respect to mor-
tality or morbidity, of protocol-based resuscita-
tion over bedside care that was provided accord-
ing to the treating physician’s judgment. We also 
found no significant benefit of the mandated 
use of central venous catheterization and central 
hemodynamic monitoring in all patients.
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